SEC Company Response from AMDOCS LTD (DOX) (CIK 0001062579) (DOX) — Mar 25, 2014
AMDOCS LTD (DOX) (CIK 0001062579)
Date: March 25, 2014 · CIK: 0001062579 · Accession: 0001193125-14-114536
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-14840
Referenced dates: March 11, 2014
Letter
SEC Letter
Jason L. Kropp
+1 617 526 6421 (t)
+1 617 526 5000 (f)
jason.kropp@wilmerhale.com
Confidential Treatment Request Under Rule 83
The entity requesting confidential treatment is:
Amdocs Limited
c/o Amdocs, Inc.
1390 Timberlake Manor Parkway
Chesterfield, MO 63017
Attn: Elizabeth W. McDermon
Secretary, Amdocs Limited
314-212-8328
March 25, 2014
VIA EDGAR AND HAND DELIVERY
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Patrick Gilmore
Re: Amdocs Limited
Form 20-F for the Fiscal Year Ended September 30, 2013
Filed December 9, 2013
File No. 001-14840
Ladies and Gentlemen:
On behalf of our client Amdocs Limited (“Amdocs” or the “Company”), we are submitting the following responses of the Company to the comments of the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) set forth in a letter dated March 11, 2014 from Mr. Patrick Gilmore, Accounting Branch Chief. The comment letter relates to the Company’s Annual Report on Form 20-F for the fiscal year ended September 30, 2013 filed December 9, 2013 (the “Form 20-F”).
For convenient reference, we have included below each of the Staff’s comments set forth in the comment letter and have keyed the Company’s responses to the numbering of the comments and the headings used in the comment letter. All of the responses are based on information provided to us by representatives of the Company.
U.S. Securities and Exchange Commission
March 25, 2014
Page 2
Form 20-F for the Fiscal Year Ended September 30, 2013
Consolidated Financial Statements
Note 16 – Contingencies
Legal Proceedings, page F-29
1. We note recent news articles regarding pending proceedings and arbitration with T-Jat Systems (2006) Ltd. Please provide us with a summarized timeline of the significant events pertaining to this matter. Tell us how you evaluated any related contingent loss disclosures related to this matter considering the guidance in ASC 450-20-50.
Rule 83 Confidential Treatment Request by Amdocs Limited Request #1
Response: [**]
Amdocs Limited respectfully requests that the information contained in Request #1 be treated as confidential information and that the Commission provide timely notice to Elizabeth W. McDermon, Secretary, Amdocs Limited, c/o Amdocs, Inc., 1390 Timberlake Manor Parkway, Chesterfield, MO 63017, telephone 314-212-8328, before it permits any disclosure of the underlined information contained in Request #1.
2. You disclose that the Company believes that the results of any such contingencies, either individually or in the aggregate, will not have a material adverse effect on the Company’s financial position, results of operations or cash flows. Please tell us what consideration was given to disclosing an estimate of reasonably possible losses in excess of amounts accrued, if material, or that such an estimate of the possible loss or range of loss cannot be made. Refer to paragraphs 3 through 5 of ASC 450-20-50.
Rule 83 Confidential Treatment Request by Amdocs Limited Request #2
Response: [**]
Amdocs Limited respectfully requests that the information contained in Request #2 be treated as confidential information and that the Commission provide timely notice to Elizabeth W. McDermon, Secretary, Amdocs Limited, c/o Amdocs, Inc., 1390 Timberlake Manor Parkway, Chesterfield, MO 63017, telephone 314-212-8328, before it permits any disclosure of the underlined information contained in Request #2.
* * * * *
Lastly, as requested by the Staff, the Company acknowledges that:
•
the Company is responsible for the adequacy and accuracy of the disclosure in the filing;
U.S. Securities and Exchange Commission
March 25, 2014
Page 3
•
Staff comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing; and
•
the Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Please do not hesitate to contact the undersigned (617-526-6421) or Robert A. Schwed (212-937-7276) of this firm with any questions regarding this response letter.
Very truly yours,
/s/ Jason L. Kropp
Show Raw Text
CORRESP 1 filename1.htm SEC Letter Jason L. Kropp +1 617 526 6421 (t) +1 617 526 5000 (f) jason.kropp@wilmerhale.com Confidential Treatment Request Under Rule 83 The entity requesting confidential treatment is: Amdocs Limited c/o Amdocs, Inc. 1390 Timberlake Manor Parkway Chesterfield, MO 63017 Attn: Elizabeth W. McDermon Secretary, Amdocs Limited 314-212-8328 March 25, 2014 VIA EDGAR AND HAND DELIVERY U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Patrick Gilmore Re: Amdocs Limited Form 20-F for the Fiscal Year Ended September 30, 2013 Filed December 9, 2013 File No. 001-14840 Ladies and Gentlemen: On behalf of our client Amdocs Limited (“Amdocs” or the “Company”), we are submitting the following responses of the Company to the comments of the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) set forth in a letter dated March 11, 2014 from Mr. Patrick Gilmore, Accounting Branch Chief. The comment letter relates to the Company’s Annual Report on Form 20-F for the fiscal year ended September 30, 2013 filed December 9, 2013 (the “Form 20-F”). For convenient reference, we have included below each of the Staff’s comments set forth in the comment letter and have keyed the Company’s responses to the numbering of the comments and the headings used in the comment letter. All of the responses are based on information provided to us by representatives of the Company. U.S. Securities and Exchange Commission March 25, 2014 Page 2 Form 20-F for the Fiscal Year Ended September 30, 2013 Consolidated Financial Statements Note 16 – Contingencies Legal Proceedings, page F-29 1. We note recent news articles regarding pending proceedings and arbitration with T-Jat Systems (2006) Ltd. Please provide us with a summarized timeline of the significant events pertaining to this matter. Tell us how you evaluated any related contingent loss disclosures related to this matter considering the guidance in ASC 450-20-50. Rule 83 Confidential Treatment Request by Amdocs Limited Request #1 Response: [**] Amdocs Limited respectfully requests that the information contained in Request #1 be treated as confidential information and that the Commission provide timely notice to Elizabeth W. McDermon, Secretary, Amdocs Limited, c/o Amdocs, Inc., 1390 Timberlake Manor Parkway, Chesterfield, MO 63017, telephone 314-212-8328, before it permits any disclosure of the underlined information contained in Request #1. 2. You disclose that the Company believes that the results of any such contingencies, either individually or in the aggregate, will not have a material adverse effect on the Company’s financial position, results of operations or cash flows. Please tell us what consideration was given to disclosing an estimate of reasonably possible losses in excess of amounts accrued, if material, or that such an estimate of the possible loss or range of loss cannot be made. Refer to paragraphs 3 through 5 of ASC 450-20-50. Rule 83 Confidential Treatment Request by Amdocs Limited Request #2 Response: [**] Amdocs Limited respectfully requests that the information contained in Request #2 be treated as confidential information and that the Commission provide timely notice to Elizabeth W. McDermon, Secretary, Amdocs Limited, c/o Amdocs, Inc., 1390 Timberlake Manor Parkway, Chesterfield, MO 63017, telephone 314-212-8328, before it permits any disclosure of the underlined information contained in Request #2. * * * * * Lastly, as requested by the Staff, the Company acknowledges that: • the Company is responsible for the adequacy and accuracy of the disclosure in the filing; U.S. Securities and Exchange Commission March 25, 2014 Page 3 • Staff comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing; and • the Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Please do not hesitate to contact the undersigned (617-526-6421) or Robert A. Schwed (212-937-7276) of this firm with any questions regarding this response letter. Very truly yours, /s/ Jason L. Kropp Jason L. Kropp